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Resume, 
133 women with chronic heart failure were analyzed for pharmacotherapy of chronic heart failure. 
The study showed that all patients who received standard CHFdrug intake were unregulated in all patients, 
inadequate type and group of drugs and inadequate therapeutic doses, and complications were low. 
Keywords: chronic heart failure, pharmacotherapy,compliance 
 
The relevance of the topic 
Modern treatment of chronic heart failure 
(CHF) is aimed not only at eliminating its 
symptoms but also preventing its emergence, 
preventing its developing, protecting the target 
parts, improving the quality of patient life, 
reducing hospitalization and the mortality rate 
[2,9]. However, despite the reduction in mortality 
from cardiovascular diseases in developed 
countries over the past three decades, there has 
been no decrease in mortality and hospitalization 
due to CHF[1,14]. 
The literature shows that there is a significant 
difference between the achievements in CHF 
pharmacotherapy and their use in clinical practice 
[4,7]. A study of EPOXA-XSN and EPOXA-O-
XSN suggests that treatment of patients with CHF 
with adverse reactions from the inpatient to the 
outpatient phase is negative [9]. This does not 
mean that the outpatient procedure is not properly 
regulated, since patients do not have sufficient 
information about their disease, lack of constant 
contact with patients at both stages and associated 
psychosomatic conditions in patients, as well as 
age, gender, social and family status. It also affects 
the treatment ofCHF, causing cases such as 
untimely implementation of these 
recommendations [6,12].It is also important to 
acknowledge that the ineffectiveness of modern 
drugs and the high mortality from CHF are also 
important factors in the strict adherence to the 
recommendations of doctors, routine, dietary and 
lifestyle guidelines [10]. 
In women, the basic treatment of CHF doesn't 
differ from men's. However, in some cases, with 
CHF pharmacotherapy, it may be necessary to 
consider some of the features of CHF in women. A 
study in Tyumen as part of the EPOXA-XSN 
program shows that male patients on outpatient 
care have a rational approach to treating CHF than 
women. According to the results, men with CHF 
had higher rates of cardiac glycoside and drug 
consumption (1.9 men and 1.4 women) [7]. F.T. 
Ageyev’s data also show that men with 
SHFsymptoms are more likely to be in the clinic 
than women [1]. The results of a study conducted 
in the framework of "Prevention and treatment of 
hypertension in the Russian Federation" show that 
men achieve 3 times more treatment and 2 times 
more effective than women. Given that the main 
etiological factor in the occurrence of CHF is 
arterial hypertension, we consider this information 
important for our analysis [7]. Failure to treat 
women often raises doubts as to whether CHF is a 
consequence of concomitant psychoemotional 
disorders. Since some studies conducted on an 
outpatient basis have shown that treatment of 
psychoemotional disorders in combination with the 
underlying disease in patients with CHF can 
increase patient adherence to recommendations 
[5,11].Some studies reported that patients reached 
CHF individual and specialized schools, improving 
their quality of life, contributing to positive 
psycho-emotional disorders in patients [6, 7]. 
Systematic monitoring of cardiovascular disease in 
each region will significantly improve inpatient 
and outpatient care [13]. Taking into account the 
foregoing, the identification of CHF medication 
therapy in women and the impact on them are of 
particular concern. 
 
The objective 
Analysis of chronic heart failure in women in 
clinical practice of pharmacotherapy  
 
Materials and methods 
 
The study involved 133 women with CHF who 
are undergoing treatment at the Department of 
Cardiology and Gerontology of the Tashkent 
Institute of Advanced Studiesof  Doctors. The 
research excluded patients with hypertrophic, 
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restrictive, obstructive, dilated cardiomyopathy, 
mainly cardiomyopathy with damage to the right 
ventricle, constructive pericarditis, primary 
pulmonary hypertension or pulmonary heart, 
myocarditis, acute myocardial infarction (within 30 
days). , unstable angina, valvular heart disease, 
acute cerebrovascular accident (6 months), renal 
and hepatic failure, autoimmune and endocrine 
disorders, patients with systemic 
collagenases.Patient functional status in chronic 
heart failure was evaluated according to the New 
York Association of Cardiologists Association 
(NYHA, 1964) criteria recommended for clinical 
practice by the International and European 
Association of Cardiologists. 
The examinations were prospective, and 
clinical evaluation of patients was carried out in a 
generally accepted manner, which included 
questioning, screening, and physical examination. 
Physical examination was performed on 
measurements of body mass, indicators of major 
vital functions (UU, AB, NS), palpation, 
percussion, auscultation. Complaints and 
anamnestic data were collected in standardized 
manner and additional questions were asked by the 
patient as needed. 
The adherence to the standard CHF treatment, 
the types and dosage of the drug, the patient's 
attitude and information about the SYUE disease 
and its treatment were determined using the 
Moriski-Green test according to the patient's 
questionnaire [15]. 
 
Research results 
The principles of drug therapy and treatment of 
any disease and heart failure, in particular in the 
second decade of the 21st century, are based on 
evidence-based medicine. In other words, only 
drugs that have proven effective with long-term 
effects (including effects on the disease) and safety 
can be recommended for widespread practice. All 
recommendations regarding the dosage and the 
quantity of doses used during the day are also based 
on controlled studies that have proven the 
effectiveness of a particular therapy method. 
Analysis of questionnaires displayed that 56 
(42.1%) women received drugs included in the 
CHF standard of therapy, 51 (38.3%) women 
received symptomatic treatment, and 11 (8.3%) 
women received drugs only during inpatient 
treatment . Overall, 88.7% of patients received 
some treatment, and 15 (11.3%) studies did not 
receive any drugs that were included in standard 
CHF treatment (Fig. 1). 
 
 
Picture-1.Duration of treatment of patients with CHF (%)
A study of the relationship between drug 
administration and CHF  FS found that, in 66.7% 
of patients diagnosed with CHF III FS, and had a 
low proportion of SYUE II FS in this group 
(33.3%). Taking into account the above figures, 
depending on the etiological factors that led to 
CHF, it was found that patients with a constant 
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intake of the drug were more likely to have arterial 
hypertension II, III and MI. 
While evaluating the effectiveness of 
treatment according to The Moriski-Green test 
showed that patients were being treated with high 
compliance of therapy in only 27 (20.3%) patients. 
In this group of patients who receive regular 
medication, there is an impression that there is a 
shortage of dosage and regular administration of 
drugs. 
Recent studies have shown that the main 
method leading to the full implementation of 
doctors' recommendations is individual interviews 
with patients and the subsequent creation of special 
schools or extensive information about CHF 
patients in these schools. The quality of patient care 
at CHF depends not only on the knowledge and 
skills of inpatient and outpatient doctors, but also 
on patients' compliance with their 
recommendations. To further increase the 
effectiveness of treatment, it is important to find 
out the reasons for non-compliance with the 
recommendations of the patient and turn to 
treatment for each patient [6, 12].Of the examined 
patients, 51.1% had information about their 
disease, but not all followed to the 
recommendations of the doctor, 21.8% of the 
patients said that the advice and recommendations 
of their doctor were unreliable, and 29.3% said that 
they did not need to follow them, 63.2% of 
respondents indicated that they would like to 
receive more and more accurate information from 
their doctors about their disease and the effects of 
drugs (Picture -2). 
 
 
Picture-2. Opinion of patients on diseases and recommendations (%)
 
As part of our study, we analyzed the use of 
evidence-based medicine principles, including the 
use of the first series of drugs that must be proven 
in the absence of evidence-based effective 
therapeutic doses and multiple daily doses. It 
should be remembered that the first set of CHF 
drug groups, including older women, was and 
remains an Aβ (or ARA) inhibitor, a β-blocker. 
When analyzing the use of drugs included in 
standard CHF treatment, the most commonly used 
drugs were angiotensin-modifying enzyme 
(AOPF) inhibitors, which accounted for 68.6% (n 
= 81) of 118 patients, and only 41 (34, 7%) of the 
patient. Regulatory administration of AOFF 
inhibitors.Although the use of this drug is relatively 
high, it should have been 100% in SYUE 
International Recommendations, taking into 
account the indications and side effects of the 
group of drugs. 
Evidence of its effectiveness and importance in 
reducing the number of deaths and hospitalizations 
in enalaprilCHF was 91.3% of the total group of 
Aβ inhibitors used, with the rest ramipril and 
lisinopril. 
The intake of angiotensin II receptor 
antagonists (ARA) was 21 (17.8%), 9 (7.6%) AOF 
inhibitors had no side effects, or the drug was 
replaced due to inefficiency, 12 (10.2). %) ARA is 
recommended from the first day of treatment. In 
the ARA group, the drug was regulated in 8 (6.8%) 
cases. 
The second place in drug use in the main group 
was β-blockers, of which 38 (32.2%) were used by 
patients, and in 18.6% they received the regimen. 
Out of the b-blockers used, 76.3% were bisoprolol, 
while the remaining 23.7% were atenolol, 
carvedilol, nebilet and metoprolol, but atenolol 
made a significant contribution. 
Patients administered diuretics, listed in the 
main group of drugs as 22.9%, cardiac glycosides 
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7.6%, and aldosterone antagonists 3.3%. 
Regarding the analysis of regularity, diuretics were 
regularly obtained in 15.3%, cardiac glycosides 
5.1% and aldosterone antagonists 1.7% (Pic. 3). 
However, despite the widespread use of 
aldosterone antagonists in accordance with medical 
recommendations for inpatients, the use of this 
drug is low. 
 
 
Pic-3 The use of drugs of the main group with standard treatment of SSC (%) 
 
Consumption of calcium antagonists from side 
effects of CHF treatment was found in 19.4% of patients 
and 26.2% of nitrates.62.7% of the antagonists were used 
in the subgroup. 
The use of 3 or more drugs in the main group of 
standard CHF treatment showed 13.5% (7.6% of the 
drugs were regulated), the use of 2 drugs was 21.1% 
(7.6% constant). 
The average therapeutic dose of the CHF standard 
treatment was 7.5 mg for AOF inhibitors and 5.5 mg for 
β-blockers, but did not reach the median dose in 
international guidelines. 
Conclusion 
1. Based on the results, 42.1% of the examined patients 
received regular CHF drugs, and only 20.3% of them had 
a high compliancerate. 
2. In the CHF study, the main group of drugs was Aβ 
inhibitors, followed by β-blockers, diuretics in are 3rd 
place, and cardiac glycosides are in 4th place. 
3. Drugs that are part of the standard CHF treatment are 
used in doses lower than the recommended therapeutic. 
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